The Correlation of Serum Adropin with Cardiovascular Risk Factors in the Experimental Rat Model of Chronic Kidney Disease and Its Implication in the Ameliorative Effect of Angiotensin-Converting Enzyme Inhibitors
Background: The risk of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD) is estimated to be far greater than that in the general population. Adropin regulates endothelial function and may play a role in the pathogenesis of CVD. Angiotensin-converting enzyme inhibitor (ACEI)...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Shiraz University of Medical Sciences
2024-12-01
|
| Series: | Iranian Journal of Medical Sciences |
| Subjects: | |
| Online Access: | https://ijms.sums.ac.ir/article_50118_191421da601a0376a534b38f750c9927.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832595705896632320 |
|---|---|
| author | Samaa Salah Abd-El-Fatah Maha A. Fathy Mohamed Ali Alabiad Raja Aljafil Mai Ahmed Gobran Enssaf A. Ahmad Ashwag S. Alsharidah Mohammed Alorini Sulaiman Mohammed Alnasser Sara A. Awadh Enas N. Morgan |
| author_facet | Samaa Salah Abd-El-Fatah Maha A. Fathy Mohamed Ali Alabiad Raja Aljafil Mai Ahmed Gobran Enssaf A. Ahmad Ashwag S. Alsharidah Mohammed Alorini Sulaiman Mohammed Alnasser Sara A. Awadh Enas N. Morgan |
| author_sort | Samaa Salah Abd-El-Fatah |
| collection | DOAJ |
| description | Background: The risk of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD) is estimated to be far greater than that in the general population. Adropin regulates endothelial function and may play a role in the pathogenesis of CVD. Angiotensin-converting enzyme inhibitor (ACEI) treatment was reported to have a protective effect on both renal and cardiovascular function. This study investigated whether adropin is associated with renal and cardiovascular outcomes after using ACEI treatment in CKD rats. Methods: In 2021, in Zagazig, Egypt, rats were assigned to: GI, control group (n=8); GII, CKD group (n=8), and GIII, CKD+captopril group (n=8), in which CKD rats received 100 mg/Kg/day captopril orally. Adropin levels, renal function, blood pressure, and various CVD risk factors were measured. Renal, cardiac, and aortic tissues were examined histologically and immunohistochemically to detect the expression of vascular endothelial growth factor receptor-2 (VEGFR-2). To analyze data, ANOVA and Pearson’s correlation tests were used (SPSS version 18, P<0.05 is significant).Results: Adropin was significantly lower in GII than in GI and GIII (P<0.001). Adropin in GII and GIII was negatively correlated with atherogenic index (P=0.019 and P=0.001, respectively), atherogenic co-efficient (P=0.012 and P=0.013, respectively), troponin I (P=0.021 and P=0.043, respectively), and nitric oxide (P=0.025 and P=0.038, respectively). VEGFR-2 expression decreased in GII and was elevated in GIII (P<0.001).Conclusion: Adropin levels were significantly correlated with most CVD risk factors in CKD and captopril-treated CKD rats, indicating a role for adropin in the pathogenesis of CVD in CKD. It also refers to its implication in the ameliorative effect of ACEI treatment, possibly by affecting VEGFR-2 and nitric oxide release. |
| format | Article |
| id | doaj-art-af7f6d8aec9f456cae5f128938fb87af |
| institution | Kabale University |
| issn | 0253-0716 1735-3688 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Shiraz University of Medical Sciences |
| record_format | Article |
| series | Iranian Journal of Medical Sciences |
| spelling | doaj-art-af7f6d8aec9f456cae5f128938fb87af2025-01-18T08:52:09ZengShiraz University of Medical SciencesIranian Journal of Medical Sciences0253-07161735-36882024-12-01491279480710.30476/ijms.2024.99442.315250118The Correlation of Serum Adropin with Cardiovascular Risk Factors in the Experimental Rat Model of Chronic Kidney Disease and Its Implication in the Ameliorative Effect of Angiotensin-Converting Enzyme InhibitorsSamaa Salah Abd-El-Fatah0Maha A. Fathy1Mohamed Ali Alabiad2Raja Aljafil3Mai Ahmed Gobran4Enssaf A. Ahmad5Ashwag S. Alsharidah6Mohammed Alorini7Sulaiman Mohammed Alnasser8Sara A. Awadh9Enas N. Morgan10Department of Anatomy and Embryology, College of Medicine, Zagazig University, Al-Sharquia, EgyptDepartment of Medical Physiology, College of Medicine, Zagazig University, Al-Sharquia, EgyptDepartment of Pathology, Faculty of Medicine, Zagazig University, Zagazig, EgyptDepartment of Pathology, Faculty of Medicine, University of Benghazi, Benghazi, LibyaDepartment of Pathology, Faculty of Medicine, Zagazig University, Zagazig, EgyptDepartment of Anatomy and Embryology, College of Medicine, Zagazig University, Al-Sharquia, EgyptDepartment of Physiology, College of Medicine, Qassim University, Buraidah, Saudi ArabiaDepartment of Pathology, College of Medicine, Qassim University, Unaizah, Kingdom of Saudi ArabiaDepartment of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Qassim, Saudi ArabiaDepartment of Biochemistry, College of Science and Art, King Abdelaziz University, Jeddah, Kingdom of Saudi ArabiaDepartment of Medical Physiology, College of Medicine, Zagazig University, Al-Sharquia, EgyptBackground: The risk of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD) is estimated to be far greater than that in the general population. Adropin regulates endothelial function and may play a role in the pathogenesis of CVD. Angiotensin-converting enzyme inhibitor (ACEI) treatment was reported to have a protective effect on both renal and cardiovascular function. This study investigated whether adropin is associated with renal and cardiovascular outcomes after using ACEI treatment in CKD rats. Methods: In 2021, in Zagazig, Egypt, rats were assigned to: GI, control group (n=8); GII, CKD group (n=8), and GIII, CKD+captopril group (n=8), in which CKD rats received 100 mg/Kg/day captopril orally. Adropin levels, renal function, blood pressure, and various CVD risk factors were measured. Renal, cardiac, and aortic tissues were examined histologically and immunohistochemically to detect the expression of vascular endothelial growth factor receptor-2 (VEGFR-2). To analyze data, ANOVA and Pearson’s correlation tests were used (SPSS version 18, P<0.05 is significant).Results: Adropin was significantly lower in GII than in GI and GIII (P<0.001). Adropin in GII and GIII was negatively correlated with atherogenic index (P=0.019 and P=0.001, respectively), atherogenic co-efficient (P=0.012 and P=0.013, respectively), troponin I (P=0.021 and P=0.043, respectively), and nitric oxide (P=0.025 and P=0.038, respectively). VEGFR-2 expression decreased in GII and was elevated in GIII (P<0.001).Conclusion: Adropin levels were significantly correlated with most CVD risk factors in CKD and captopril-treated CKD rats, indicating a role for adropin in the pathogenesis of CVD in CKD. It also refers to its implication in the ameliorative effect of ACEI treatment, possibly by affecting VEGFR-2 and nitric oxide release.https://ijms.sums.ac.ir/article_50118_191421da601a0376a534b38f750c9927.pdfadropinrenal insufficiencychronic kidney diseaseheart disease risk factorspeptidyl-dipeptidase a |
| spellingShingle | Samaa Salah Abd-El-Fatah Maha A. Fathy Mohamed Ali Alabiad Raja Aljafil Mai Ahmed Gobran Enssaf A. Ahmad Ashwag S. Alsharidah Mohammed Alorini Sulaiman Mohammed Alnasser Sara A. Awadh Enas N. Morgan The Correlation of Serum Adropin with Cardiovascular Risk Factors in the Experimental Rat Model of Chronic Kidney Disease and Its Implication in the Ameliorative Effect of Angiotensin-Converting Enzyme Inhibitors Iranian Journal of Medical Sciences adropin renal insufficiency chronic kidney disease heart disease risk factors peptidyl-dipeptidase a |
| title | The Correlation of Serum Adropin with Cardiovascular Risk Factors in the Experimental Rat Model of Chronic Kidney Disease and Its Implication in the Ameliorative Effect of Angiotensin-Converting Enzyme Inhibitors |
| title_full | The Correlation of Serum Adropin with Cardiovascular Risk Factors in the Experimental Rat Model of Chronic Kidney Disease and Its Implication in the Ameliorative Effect of Angiotensin-Converting Enzyme Inhibitors |
| title_fullStr | The Correlation of Serum Adropin with Cardiovascular Risk Factors in the Experimental Rat Model of Chronic Kidney Disease and Its Implication in the Ameliorative Effect of Angiotensin-Converting Enzyme Inhibitors |
| title_full_unstemmed | The Correlation of Serum Adropin with Cardiovascular Risk Factors in the Experimental Rat Model of Chronic Kidney Disease and Its Implication in the Ameliorative Effect of Angiotensin-Converting Enzyme Inhibitors |
| title_short | The Correlation of Serum Adropin with Cardiovascular Risk Factors in the Experimental Rat Model of Chronic Kidney Disease and Its Implication in the Ameliorative Effect of Angiotensin-Converting Enzyme Inhibitors |
| title_sort | correlation of serum adropin with cardiovascular risk factors in the experimental rat model of chronic kidney disease and its implication in the ameliorative effect of angiotensin converting enzyme inhibitors |
| topic | adropin renal insufficiency chronic kidney disease heart disease risk factors peptidyl-dipeptidase a |
| url | https://ijms.sums.ac.ir/article_50118_191421da601a0376a534b38f750c9927.pdf |
| work_keys_str_mv | AT samaasalahabdelfatah thecorrelationofserumadropinwithcardiovascularriskfactorsintheexperimentalratmodelofchronickidneydiseaseanditsimplicationintheameliorativeeffectofangiotensinconvertingenzymeinhibitors AT mahaafathy thecorrelationofserumadropinwithcardiovascularriskfactorsintheexperimentalratmodelofchronickidneydiseaseanditsimplicationintheameliorativeeffectofangiotensinconvertingenzymeinhibitors AT mohamedalialabiad thecorrelationofserumadropinwithcardiovascularriskfactorsintheexperimentalratmodelofchronickidneydiseaseanditsimplicationintheameliorativeeffectofangiotensinconvertingenzymeinhibitors AT rajaaljafil thecorrelationofserumadropinwithcardiovascularriskfactorsintheexperimentalratmodelofchronickidneydiseaseanditsimplicationintheameliorativeeffectofangiotensinconvertingenzymeinhibitors AT maiahmedgobran thecorrelationofserumadropinwithcardiovascularriskfactorsintheexperimentalratmodelofchronickidneydiseaseanditsimplicationintheameliorativeeffectofangiotensinconvertingenzymeinhibitors AT enssafaahmad thecorrelationofserumadropinwithcardiovascularriskfactorsintheexperimentalratmodelofchronickidneydiseaseanditsimplicationintheameliorativeeffectofangiotensinconvertingenzymeinhibitors AT ashwagsalsharidah thecorrelationofserumadropinwithcardiovascularriskfactorsintheexperimentalratmodelofchronickidneydiseaseanditsimplicationintheameliorativeeffectofangiotensinconvertingenzymeinhibitors AT mohammedalorini thecorrelationofserumadropinwithcardiovascularriskfactorsintheexperimentalratmodelofchronickidneydiseaseanditsimplicationintheameliorativeeffectofangiotensinconvertingenzymeinhibitors AT sulaimanmohammedalnasser thecorrelationofserumadropinwithcardiovascularriskfactorsintheexperimentalratmodelofchronickidneydiseaseanditsimplicationintheameliorativeeffectofangiotensinconvertingenzymeinhibitors AT saraaawadh thecorrelationofserumadropinwithcardiovascularriskfactorsintheexperimentalratmodelofchronickidneydiseaseanditsimplicationintheameliorativeeffectofangiotensinconvertingenzymeinhibitors AT enasnmorgan thecorrelationofserumadropinwithcardiovascularriskfactorsintheexperimentalratmodelofchronickidneydiseaseanditsimplicationintheameliorativeeffectofangiotensinconvertingenzymeinhibitors AT samaasalahabdelfatah correlationofserumadropinwithcardiovascularriskfactorsintheexperimentalratmodelofchronickidneydiseaseanditsimplicationintheameliorativeeffectofangiotensinconvertingenzymeinhibitors AT mahaafathy correlationofserumadropinwithcardiovascularriskfactorsintheexperimentalratmodelofchronickidneydiseaseanditsimplicationintheameliorativeeffectofangiotensinconvertingenzymeinhibitors AT mohamedalialabiad correlationofserumadropinwithcardiovascularriskfactorsintheexperimentalratmodelofchronickidneydiseaseanditsimplicationintheameliorativeeffectofangiotensinconvertingenzymeinhibitors AT rajaaljafil correlationofserumadropinwithcardiovascularriskfactorsintheexperimentalratmodelofchronickidneydiseaseanditsimplicationintheameliorativeeffectofangiotensinconvertingenzymeinhibitors AT maiahmedgobran correlationofserumadropinwithcardiovascularriskfactorsintheexperimentalratmodelofchronickidneydiseaseanditsimplicationintheameliorativeeffectofangiotensinconvertingenzymeinhibitors AT enssafaahmad correlationofserumadropinwithcardiovascularriskfactorsintheexperimentalratmodelofchronickidneydiseaseanditsimplicationintheameliorativeeffectofangiotensinconvertingenzymeinhibitors AT ashwagsalsharidah correlationofserumadropinwithcardiovascularriskfactorsintheexperimentalratmodelofchronickidneydiseaseanditsimplicationintheameliorativeeffectofangiotensinconvertingenzymeinhibitors AT mohammedalorini correlationofserumadropinwithcardiovascularriskfactorsintheexperimentalratmodelofchronickidneydiseaseanditsimplicationintheameliorativeeffectofangiotensinconvertingenzymeinhibitors AT sulaimanmohammedalnasser correlationofserumadropinwithcardiovascularriskfactorsintheexperimentalratmodelofchronickidneydiseaseanditsimplicationintheameliorativeeffectofangiotensinconvertingenzymeinhibitors AT saraaawadh correlationofserumadropinwithcardiovascularriskfactorsintheexperimentalratmodelofchronickidneydiseaseanditsimplicationintheameliorativeeffectofangiotensinconvertingenzymeinhibitors AT enasnmorgan correlationofserumadropinwithcardiovascularriskfactorsintheexperimentalratmodelofchronickidneydiseaseanditsimplicationintheameliorativeeffectofangiotensinconvertingenzymeinhibitors |